Skip to main content

Table 2 Percentages of incident hemodialysis and peritoneal dialysis patients with prescriptions for specific blood pressure medications at 6 months, by race/ethnicity, 2003–2008

From: Patterns in blood pressure medication use in US incident dialysis patients over the first 6 months

 

Hemodialysis, n=12,159

Peritoneal dialysis, n = 913

Medication

All

Black

White

Other

Hispanic

All

Black

White

Other

Hispanic

n

 

4543

7075

541

679

 

256

607

50

33

None

12

10

13

13

11

10

8

10

xx

xx

Beta-blocker

          

  Any

59

60

59

58

55

55

54

55

56

42

  Alpha-beta

19

20

18

16

14

13

14

13

xx

xx

  Beta not alpha

41

40

41

42

41

42

40

42

44

30

RAS*

          

  Any

45

49

43

48

51

52

52

53

38

48

  ACEI

32

36

29

33

39

33

32

34

20

xx

  ARB

17

18

17

18

16

23

23

22

26

xx

CCB

          

  Any

49

57

43

49

55

50

55

37

50

45

  DHP

40

48

34

43

48

40

48

35

48

39

  Non-DHP

9

8

9

6

7

10

7

12

xx

xx

Diuretic†

          

  Any

28

23

31

29

33

41

32

45

42

45

  Loop

26

21

29

26

32

38

31

42

36

42

  Thiazide

5

4

5

5

5

9

6

10

xx

xx

Alpha blocker

7

7

7

4

5

10

10

10

xx

xx

Central alpha 2 agonist

19

27

15

12

19

15

21

14

xx

xx

Hydralazine

8

10

7

5

9

4

6

3

xx

xx

Minoxidil

4

6

3

3

2

2

5

2

xx

xx

  1. Note: Values are percentages except for the n row, which represents numbers of patients.
  2. ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; DHP, dihydropyridine; RAS, renin angiotensin system agent.
  3. *Renin-inhibitors comprised < 1% of RAS agents from 2003–2008.
  4. †Potassium-sparing diuretics comprised < 1% of diuretic agents from 2003–2008.
  5. xx represents less than 10 persons per cell; these percentages have been suppressed.
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us